Form 4: Abbott Laboratories Director Nancy McKinstry Reports Acquisition of Shares and Stock Options

Director Nancy McKinstry reports acquisition of Abbott Laboratories common shares and stock options under the company's incentive stock program.

Summary

• Nancy McKinstry, a director of Abbott Laboratories, reported a transaction involving the acquisition of common shares and stock options.
• On April 26, 2024, McKinstry acquired 1,866 common shares without par value at a price of $0, bringing her total direct ownership to 37,089 shares.
• On the same date, McKinstry also acquired 6,850 stock options with an exercise price of $107.14, exercisable from April 26, 2024, until April 25, 2034.
• These transactions were made under the Abbott Laboratories 2017 Incentive Stock Program.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, reflecting standard insider trading activity. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions are governed by SEC regulations to ensure transparency and prevent insider trading.

Key Dates